NCT05346198View on ClinicalTrials.gov

Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 12, 2021

Primary Completion Date

July 31, 2022

Study Completion Date

December 31, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

CART-BCMA

The CART-BCMA (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.

Trial Locations (2)

Unknown

Hematology Department of the First Affiliated Hospital of Zhejiang University, Hangzhou

Hematology Department of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Shanghai Simnova Biotechnology Co.,Ltd.

INDUSTRY